Does PGNY pay a dividend and is it safe?

Progyny Inc. (PGNY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PGNY / dividends

AGL (36) SHC (49) DVA (74) FMS (57) ⌘ Pro Terminal →

Progyny Inc. (PGNY) Dividend Safety Gauge & 10-Year DRIP Compounder

$29.41 +0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.52

Progyny Inc. (PGNY) earns a Roarable Rating of B+ (Buy) with 79/100 RQD Confidence. High-quality cash engine (23.6% gross margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.24B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PGNY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PGNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Progyny Inc. (NASDAQ: PGNY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 79/100 at a spot price of $29.41 (+0.75% 1D, market cap $2.24B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, PGNY ranks #18 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PGNY compare to AGL and SHC in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), PGNY carries a Roarable B+ (79/100 RQD), trailing P/E of 37.2x, gross margin of 23.6%, and ROIC of 16.7%. By comparison, AGL (agilon health inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PGNY?

▼

Per PGNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551306), Progyny Inc. generated $1.29B in revenue (+10.4% YoY), $58.5M in net income, and $191.8M in free cash flow against $742.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (23.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $29.52 (+0.38%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 14.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 79/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.1% avg 90D alpha vs SPY • 71.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGNY)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (79/100 Composite)

🔍 WHY PGNY SCORES 79/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 14.9% FCF Margin ($191.8M FCF) & 23.6% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (20% of score)

20D Institutional Volume Accumulation (±7.3% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit15/20 pts (-5 pt drag)

Macro rate sensitivity & RSI-14 (59.9) create a -5 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$27.39+4.3% Next Q

Q2 (-2Q)

Grade B+$28.58-3% Next Q

Q3 (-1Q)

Grade B+$27.72+6.1% Next Q

Current

Grade B+$29.41+8.1% Hist 90D α

Trajectory: B (71) → B+ (79)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PGNY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 79/100 (B+) score, PGNY faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 21.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.01) or 200D SMA ($24.40) invalidates the momentum regime and cuts Target Base ($32.19) toward Bear Floor ($24.12).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PGNY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PGNY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 79%NO 21%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $20,610

Est. Year-10 Shareholder Yield: $371/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.8K

Yr 1

$11.6K

Yr 2

$12.4K

Yr 3

$13.4K

Yr 4

$14.4K

Yr 5

$15.4K

Yr 6

$16.6K

Yr 7

$17.8K

Yr 8

$19.2K

Yr 9

$20.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in PGNY & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on PGNY and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PGNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.53%▲ RESISTANCE BREAKOUT

2026-11-03O $28.40H $29.41L $28.40C $29.41VOL 807.8K

RES: $23.52SUP: $23.80SMA50: $27.01SMA200: $24.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PGNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PGNY Butterfly Map → + Track PGNY →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

28.5%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PGNY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PGNY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PGNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGNY)

Health Care Rank #18 of 1015 ⚔️ AGL vs PGNY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PGNY vs. AGL, SHC, DVA, FMS)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Progyny Inc. (PGNY) ranks #18 by composite RQD confidence (79/100, grade B+) and #236 by equity capitalization ($2.24B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently leads its immediate peer cohort in composite quantitative strength at 79/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PGNY ACTIVE Progyny Inc.	B+	79/100	37.2x	23.6%	16.7%	+0.75%	$2.24B	Benchmark Subject
AGL agilon health inc.	D-	36/100	—	—	-35.0%	+2.04%	$1.43B	/agl-vs-pgny →
SHC Sotera Health Company	D	49/100	68.5x	55.5%	3.1%	-2.26%	$5.18B	/shc-vs-pgny →
DVA DaVita Inc.	B	74/100	11.4x	—	29.2%	-0.94%	$11.79B	/dva-vs-pgny →
FMS Fresenius Medical Care AG American	D+	57/100	32.8x	—	9.9%	+0.62%	$12.55B	/fms-vs-pgny →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001551306 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Progyny Inc. (PGNY) reported GAAP revenue of $1.29B (+10.4% vs. FY2024 revenue of $1.17B , and +18.4% cumulative change since FY2023) , GAAP net income of $58.5M, operating cash flow of $210.2M, and free cash flow of $191.8M (+10.4% YoY). On the balance sheet, PGNY closed FY2025 with $742.4M in total assets against $0 in total debt (Altman Z-Score: 8.84, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.29B	$58.5M	$210.2M	$191.8M	$742.4M	—
FY2024 (FY)	2024-12-31	$1.17B	$54.3M	$179.1M	$173.7M	$607.1M	—
FY2023 (FY)	2023-12-31	$1.09B	$62.0M	$188.8M	$188.8M	—	—

3. PGNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PGNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PGNY compare to AGL and SHC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PGNY?

Where is PGNY trading relative to its 50-day, 200-day, and 52-week technical levels?

PGNY last traded at $29.41 (+0.75% on volume of 1,351,262 shares), positioning the stock +8.89% above its 50-day simple moving average ($27.01) and +20.53% above its 200-day simple moving average ($24.40). Across its 52-week range of $16.10 to $33.06, PGNY sits at the 78.5% percentile with a 14-day RSI of 59.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.3% ($27.26 to $31.56).

Direct Sub-Reports: PGNY RQD Cockpit PGNY 12M Forecast PGNY Earnings & Move PGNY Dividends & DRIP PGNY Insiders & 13F PGNY Whale Options PGNY Profit Sankey PGNY News & Why

ROARABLE RATING BRIEF • RQD 79/100 (B+) ✓ SEC XBRL & RQD VERIFIED

PGNY — Progyny Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Progyny Inc. (PGNY) earns a live Roarable RQD composite score of 79/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $29.41 (+0.75% 1D, market capitalization $2.24B).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 16.7%, gross margin of 23.6%, operating margin of 6.6%, and free cash flow yield of 8.80%.
Whale 13F & Options Flow (16/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.84, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Progyny Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Misc Health and Biotechnology Services industry. The company generated FY 2025 revenue of $1.29B, indicating scale in its reported operations.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Progyny Inc. (PGNY) reported $1.29B in annual revenue (up from $1.17B in FY2024, +10.4% YoY) and $58.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.09B revenue, $62.0M net income) through FY2025, PGNY scaled operating cash flow to $210.2M and free cash flow to $191.8M, backed by $742.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 79/100): Strong cash generator (23.6% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $16.10 – $33.06 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 37.2x trailing P/E and 20.5x EV/EBITDA against 6.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the supplied data. Investors should note that the absence of graph links means ripple effects are not quantified here. Sector context is limited to the Health Care classification and the beta of 1.0.

Key Question #1: Can PGNY sustain or expand its 6.6% operating margin and 16.7% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.29B and free cash flow of $191.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is PGNY's 34.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PGNY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Progyny Inc. (PGNY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PGNY Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 1d ago

Why Are Progyny (PGNY) Shares Soaring Today

Yahoo Finance report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

PGNY: Progyny Inc Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Trefis • 1d ago

What Does Progyny’s Falling Multiple Really Say?

Trefis report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

Progyny Inc (NASDAQ:PGNY): Strong Growth With a Bull Flag Technical Setup

ChartMill report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Progyny (PGNY) Stock Looks About Right On Its 56% Run

Yahoo Finance report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Progyny (PGNY) Gains 1.2 Million Covered Lives, Shares Rise 6% o

GuruFocus report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Progyny (PGNY) Shares Just Moved, So What Is Driving Attention Now?

Simply Wall St report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Progyny (PGNY) Cuts Guidance And Puts Its Valuation Back In Focus

Yahoo Finance report covering Progyny Inc. (PGNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PGNY Bull vs. Bear Conversation Board — What's Your Call at $29.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PGNY 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $34.44 (+18.0%)

📌 Pinned Debate

Strong cash engine with 16.7% ROIC and 8.8% FCF yield, supported by an 8.84 Altman Z-Score.

Here is why I am bullish on PGNY here at $29.19: Strong cash engine with 16.7% ROIC and 8.8% FCF yield, supported by an 8.84 Altman Z-Score.. Compare PGNY's 6.6% operating margin and 16.7% ROIC against the rest of Misc Health and Biotechnology Services. As long as cash conversion holds up, dips toward $27.73 are getting bought.

CapAlloc_Nerd 🐂 BULL

@BreakoutHunter Agree on the RQD 79/100 quality, though with 1.0 beta I'm scaling in with half-size at $29.19 and keeping dry powder in case we test $27.15.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $22.18 (-24.0%)

Spot @ $29.19

A 37.2 trailing P/E and declining cash balance leave little valuation margin if execution slips.

A 37.2 trailing P/E and declining cash balance leave little valuation margin if execution slips.. Look at the math on PGNY: paying 37.2x trailing P/E for 16.7% ROIC and 6.6% operating margins leaves zero margin of safety if Misc Health and Biotechnology Services demand softens. I'd wait for a retest of $25.69 before getting long.